News

Parkinson’s Institute and Clinical Center and Retrotope have paired up to explore the therapeutic potential of the investigational agent RT001 in patients with progressive supranuclear palsy (PSP), a type of treatment-resistant Parkinson’s disease. Under Retrotope’s expanded access program for RT001, the institute’s physicians started dosing two…

The Linked Clinical Trials (LCT) Initiative, a repurposing program that aims to identify existing medicines which can slow the progression of Parkinson’s disease, has resulted in a growing number of clinical trials. The partnership’s history, purpose and activities are the focus of an article, “The Linked Clinical…

The time between diagnosis and implementation of symptomatic treatment is critical in the effort to find a cure for Parkinson’s disease. However, many early Parkinson’s patients wait too long before seeking medical attention, leaving researchers with a small group of candidates for clinical trials, says Robert A. Hauser,…

If the FDA approves Sunovion’s APL-130277 come January, Parkinson’s patients will have a first oral treatment — and a first new treatment in more than a decade — for off episodes, those times of difficulties with movement despite taking treatments that stimulate dopamine receptors, like levodopa. “We think that…

People with inflammatory bowel disease (IBD), an umbrella name for disorders marked by prolonged inflammation of the digestive tract, are at a higher-than-usual risk for Parkinson’s disease, a review study involving 8.9 million IBD patients suggests. The study, “The risk of Parkinson’s disease in inflammatory bowel disease: A…

In 2017, the United Kingdom’s National Institute for Health and Care Excellence (NICE) published its latest guidelines on how adult patients and their caregivers should manage Parkinson’s disease (PD). In a new commentary, four experts discuss the implications of some of these recommendations for both patients and healthcare professionals,…

The new law calling for the federal government to collect data on U.S. residents with neurological conditions such as Parkinson’s will help refine disease research and make care more accessible, the Michael J. Fox Foundation (MJFF) for Parkinson’s Research said. President Donal Trump recently signed into law the Labor,…

Sensile Medical, a subsidiary of Gerresheimer, is going to launch its wearable micro pump to deliver liquid medicines to patients in Europe who have advanced Parkinson’s disease. The medical device was given the European Union’s CE declaration of conformity, a prerequisite for a product to enter the European…

A new tool to measure fear of falling may help improve patients’ personalized care, reduce the risk of falls, and enhance physical and social activity among patients with Parkinson’s disease, a study reports. The study, “Differentiating cognitive or motor dimensions…

A newly identified small molecule compound, called SynuClean-D, can prevent the formation of toxic alpha-synuclein aggregates, disrupt the propagation of amyloid fibrils, and rescue nerve cells from alpha-synuclein-induced death in an animal model of Parkinson’s disease, a study shows. Given this particular activity, SynuClean-D may be a promising candidate…